Adalimumab
Upadacitinib, deucravacitinib ‘the top two’ small molecules for psoriatic arthritis
Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic arthritis, according to data published in Therapeutic Advances in Musculoskeletal Disease.
Direct switch from TNFi to tofacitinib shows ‘acceptable’ safety in psoriatic arthritis
For patients with psoriatic arthritis, switching directly from adalimumab to tofacitinib with no washout period presents no increased safety risks, according to data published in Arthritis Research & Therapy.
VIDEO: A roundup of important abstracts presented at ACR 2024
WASHINGTON — In this video, Ambreesh Chawla, MD, summarizes salient and practice-changing presentations in rheumatoid arthritis from ACR Convergence 2024.
Abatacept, adalimumab yield ‘identical’ responses in early rheumatoid arthritis
WASHINGTON — Patients in early rheumatoid arthritis respond well to either abatacept or adalimumab, with the critical factor for both treatments being prompt initiation, according to data presented at ACR Convergence 2024.
VIDEO: Biosimilar use, education highlighted at ACR
WASHINGTON — In this video, Micaela F. Bayard, MD, highlights a conversation on the evolution of biosimilars from ACR Convergence 2024.
Median survival of first-line TNF inhibitor in ankylosing spondylitis nearly 11 years
Patients with ankylosing spondylitis starting their first TNF inhibitor, and who stayed on said treatment for at least 2 years, demonstrated a median drug survival period of 10.6 years, with 24% discontinuing, according to data.
Certolizumab pegol superior to adalimumab in patients with rheumatoid arthritis, high RF
Patients with rheumatoid arthritis and high rheumatoid factor demonstrate better clinical outcomes, and maintain drug concentration, when treated with certolizumab pegol vs. adalimumab, according to data published in Rheumatology.
Adalimumab slashes Behçet’s uveitis relapse rate significantly more than cyclosporine
Adalimumab combined with corticosteroids led to a significantly lower rate of relapse in Behçet’s disease uveitis vs. cyclosporine alongside corticosteroids, according to data published in The Lancet Rheumatology.
Biosimilar retention not impacted by comorbidities in inflammatory RMDs
The presence of comorbidities with inflammatory rheumatic musculoskeletal diseases made little difference in biosimilar retention after a non-medical switch, according to data published in Arthritis Research & Therapy.
First-line treatment with vedolizumab linked to fewer hospitalizations, surgeries in IBD
The treatment sequence of vedolizumab to adalimumab resulted in the lowest overall incidences of hospitalization and surgery in both Crohn’s disease and ulcerative colitis compared with other biologic treatment sequences, research showed.